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Myostatin is a potent inhibitor of muscle growth. Genetic deletion of Myostatin leads to massive hyperplasia and
hypertrophy of skeletal muscle. However, the overall muscle pattern is preserved. We show that, during chick embryonic
development, Myostatin is expressed at stages and positions unlikely to influence qualitative muscle development. In the
somites, Myostatin is predominantly expressed in a central domain of the dermomyotome but not at the dorsomedial and
ventrolateral lips, where most cells for myotomal elongation are recruited. During limb bud development, Myostatin is
transiently expressed at early stages in both myogenic and nonmyogenic regions. Myostatin is reexpressed during limb bud
development at a time when splitting of muscle is underway. Heterotopically developed wing buds that fail to form muscle
still express Myostatin. This demonstrates that, in the limb, not all Myostatin-expressing cells are of myogenic origin.
Ectoderm and Sonic hedgehog have different effects on the expression of Myostatin dependent on stages at which the
operation was performed and the length of the postoperative period. Finally, we show that application of Myostatin protein
into the developing limb bud results in a down-regulation of Pax-3 and Myf-5, both genes associated with proliferation of
myogenic cells; and, furthermore, Myostatin also prevents the expression of MyoD, a gene associated with muscle
differentiation. The long-term effect of Myostatin treatment leads to a deficiency of limb muscle. Therefore, Myostatin
negatively affects gene expression of transcription factors, which are necessary for establishing myogenic cell
identity. © 2002 Elsevier Science (USA)
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Regulation of body size is one of the most fascinating
aspects of developmental biology, as animals even within a
species can display tremendous differences in proportion
without changing the basic body plan. The development of
the muscle mass has been of intensive research interest
because it can significantly vary in its bulk without chang-
ing the structure of the whole body (Christ et al., 2001).
Numerous studies suggest that the development of muscle
1 These authors contributed equally to this work.
2 To whom correspondence should be addressed. Fax: 0207-© 2002 Elsevier Science (USA)
All rights reserved.is regulated by secreted factors originating from both myo-
genic and nonmyogenic sources.
We have previously presented data which suggest that
bone morphogenetic proteins (BMPs), members of the
TGF- superfamily of secreted proteins, and their antago-
nists Follistatin and Noggin may influence embryonic
muscle growth (Amthor et al., 1999, 2002). During embry-
onic development, factors such as BMPs have been impli-
cated not only in regulating the growth but also in the final
positioning of muscle (Amthor et al., 1998).
However, the influence of TGF- family members on
muscle development has been most dramatically demon-
strated following the genetic deletion of Myostatin (also
known as GDF-8). Myostatin-null mice display a dramatic
widespread phenotype, with muscle of mutant animals388-1027. E-mail: kpatel@rvc.ac.uk.
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FIG. 2. Tissue expression of Myostatin during somite development. (A, B) Myostatin expression in the central domain of the
dermomyotome at interlimb level at HH stage 20 (A, arrow) and in cells ventral to the dermomyotome (A, B, arrowheads). (C) Transverse
section through the centre of a somite at interlimb level of an HH stage 22 embryo shows Myostatin expression in the dermomyotome
(arrow) but no expression in the dorsomedial and ventrolateral dermomyotomal lips. Note that there is no expression in the myotome
(arrowheads). (D) Transverse section through the cranial part of a somite at interlimb level of same embryo as shown in (C) (HH stage 22).
At this somite level, the myotome does express Myostatin (arrowheads) additionally to the dermomyotomal expression (arrow). (E)
Myostatin expression in the dermomyotome (arrows) and in the hypaxial part of the myotome (black arrowheads) and in the most dorsally
located myotomal tip (white arrowhead) at interlimb level of HH stage 25 somites. (F) Myostatin expression in the dermomyotome (arrow)
and in the rostral and caudal part of the myotome at interlimb level (arrowheads) after longitudinal sectioning of an HH stage 25 embryo.
FIG. 1. Developmental time course of avian embryonic Myostatin expression. (A) Myostatin expression in the two most caudally situated
somites (black arrow), lateral aspects of occipital somites (red arrowhead), and in the tail bud (black arrowhead) at HH stage 15. (B)
Myostatin expression in the ventral part of occipital and cervical somites and cells which migrate in the tongue (red arrowhead) at HH stage
17. (C) Myostatin expression in the medial part of somites at interlimb level (black arrowhead), in the ventral part of occipital and cervical
somites, and in cells which migrate in the tongue (red arrowhead) at HH stage 19. (D) Myostatin expression in all somites (except tailbud
somites) and prospective tongue muscle (red arrowhead) at HH stage 20. Expression is confined to the central somite part and excluded of
the dorsomedial and ventrolateral somite part. Additionally, Myostatin is expressed as a continuous band laterally to somites (black
arrows). (E) Myostatin expression in somites similar to (D) and first expression in a proximocentral domain of limb buds (red arrowheads)
at HH stage 21. (F) Distal extension of centrally located Myostatin expression domain in limb buds (red arrowheads) at HH stage 22. At
trunk level, Myostatin expression extends to the tail bud somites and expression declines in occipital and cervical somites. (G) Myostatin
expression extends more dorsomedially and ventrolaterally in interlimb somites at HH stage 25 compared with younger stages. Additional
up-regulation of Myostatin expression at the most dorsomedial part of the somites (black arrowheads). Expression in the wing bud (red
arrowhead). (H) High expression in the hypaxial part of the myotomes at interlimb level at HH stage 27. Expression in the wing bud declines
(red arrowhead). (I) Dorsal view at an HH stage 29 embryo. Expression is found only in some muscles of the wing bud (red arrowhead). (J)
Ventral view of embryo shown in (I). Expression only in hypaxial trunk muscle (black arrow). (K, L) Dorsal view (K) and ventral view (L)
of an HH stage 32 wing bud. Expression is found in some but not all wing muscles.
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weighing two to three times that of wild-type mice
(McPherron and Lee, 1997). Muscle enlargement is due to
an increase in the number of muscle fibres (hyperplasia) and
to an increase in the size of individual muscle fibres
(hypertrophy). Myostatin may act in a threshold-dependent
manner because reduction in protein level results in muscle
hypertrophy but not in hyperplasia (Zhu et al., 2000).
Therefore, negative size control is an important tool in
developmental biology, which functions independently of
patterning control and can be executed by a diffusible
factor.
Following the isolation of Myostatin, numerous groups
have determined that breeds of cattle, including Piedmon-
tese and Belgian Blue, which are characterised by excessive
muscle development (Muscle doubling), harbour mutations
in the coding region of the Myostatin gene (Kambadur et al.,
1997; McPherron and Lee, 1997). However, the develop-
mental need to negatively regulate muscle size is not clear.
Recent studies have detected Myostatin in tissues other
than skeletal muscle, including the mammary gland and
Purkinje fibres of the heart, which implies additional yet
unexplored functions of Myostatin (Ji et al., 1998; Sharma
et al., 1999). Interestingly, Myostatin is expressed in injured
and regenerating muscle; patients suffering from AIDS-
related muscle wasting show elevated serum levels of
Myostatin (Gonzalez-Cadavid et al., 1998; Kirk et al., 2000;
Sakuma et al., 2000). However, the function of Myostatin in
these pathological conditions remains to be determined.
Myostatin is expressed in muscle during embryonic,
foetal, and at a very low extent in adult life (Lee and
McPherron, 1999). The exact molecular mechanism of
muscle growth inhibition is not exactly known. In vitro
analysis has shown a repression of myoblast proliferation
(Taylor et al., 2001; Thomas et al., 2000). It is not known
whether Myostatin exerts the same activity on myogenic
cells during different stages of development because the
structure and cellular properties of muscle change consid-
erably during embryonic, foetal, and neonatal life (Miller
and Stockdale, 1986; Stockdale, 1992). Furthermore, the
response of myogenic cells to a particular environmental
cue might differ during successive stages of development.
All skeletal musculature of vertebrates, with the excep-
tion of some head muscles, originates from paraxial meso-
derm (Christ and Ordahl, 1995). Cells of paraxial mesoderm
form transient epithelial structures, called somites. As well
as being the source of skeletal muscle, the somites of higher
vertebrates also give rise to cartilaginous tissue, including
vertebrae, ribs, and dorsal dermis. During somite develop-
ment, somite cells are committed to their prospective fate
dependent on their location within the somite and proxim-
ity to signals from adjacent tissues. Only cells of the dorsal
half of the somites retain myogenic potential and reside
within the epithelial dermomyotomal layer underneath the
surface ectoderm. The ventral half of the somites deepithe-
lialises and forms the sclerotome, the precursor of vertebrae
and ribs.
Muscle cells are recruited only from the edges of the
dermomyotome and form the myotome, which morpho-
logically resembles a sheet of cells situated underneath the
dermomyotome (Cinnamon et al., 1999; Denetclaw and
Ordahl, 2000; Huang and Christ, 2000; Kahane et al., 1998).
As dermomyotomal cells are recruited to form the myo-
tome, the muscle differentiation programme is initiated by
the expression of the myogenic regulatory factors MyoD
and Myf-5 (Pownall and Emerson, 1992). Initially, recruit-
ment of myogenic precursors takes places mainly at the
dorsomedial and ventrolateral edges of the dermomyotome,
which enables dorsomedial (epaxial) and ventrolateral (hy-
paxial) elongation of the myotome (Cinnamon et al., 1999;
Denetclaw et al., 2001; Huang and Christ, 2000; Ordahl et
al., 2001). It is not known why myotomal cells are recruited
at these sites because experimental manipulations have
shown that all cells of the dermomyotome can be instanta-
neously induced to form muscle. Although this leads to an
initial thickening of the myotome, subsequent muscle
development is impeded due to the depletion of the reser-
voir of proliferating muscle precursors (Amthor et al.,
1999). This suggests the existence of muscle inhibitor(s)
that regulates the recruitment of dermomyotomal cells for
myotomal development, ensuring a stable population of
precursors which enables long-term growth of muscle.
At occipital and limb levels, small populations of cells
delaminate from the ventrolateral edge of the dermomyo-
tome and migrate into adjacent mesenchyme to form the
skeletal muscle of the tongue and limbs (Chevallier et al.,
1977; Christ et al., 1974; Huang et al., 1999). After myo-
genic cells migrate into limb bud mesenchyme, they form
premuscle masses that are situated at the dorsal and ventral
aspects of the limb buds. Premuscle masses consist of
subectodermally located undifferentiated, proliferating
muscle precursors (marked by the expression of Pax-3) and
differentiating muscle cells (marked by the expression of
MyoD), which are situated more towards the mesenchymal
centre of the limb (Amthor et al., 1998). Only after having
down-regulated Pax-3 expression do myogenic cells initiate
the differentiation programme. During initial limb out-
growth, premuscle masses simply enlarge by extension in
all axes. From HH stage 28 onwards, however, premuscle
masses split into individual blocks, and at HH stages 31–32,
all different limb muscles are formed.
A previous study has analysed the expression of Myosta-
tin in the chick by using RT-PCR, which generated tempo-
ral but no spatial data (Kocamis et al., 1999). We therefore
have carried out a temporospatial examination of the ex-
pression of chick Myostatin and present the first detailed
profile of Myostatin expression during vertebrate develop-
ment. Our work shows that the expression of Myostatin is
initiated relatively late during somite development, i.e., a
considerable time after the formation of the sclerotome,
dermomytome, and myotome. Myostatin is expressed in
the central part of the dermomyotome but not in the
dorsomedial and ventrolateral lips. Myostatin was also
detected in the subectodermal mesenchyme, the site of
dorsal dermis precursors, and in the myotome. During late
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embryonic stages, Myostatin is expressed in hypaxial but
not in epaxial muscle. We show that, during limb develop-
ment, Myostatin is initially expressed in myogenic cells
and additionally in nonmyogenic cells of the mesenchymal
core. Myostatin becomes localised to specific limb muscles
only at late stages of embryonic development. To identify
the environmental influences that regulate the expression
of Myostatin and to identify the type of cells which express
Myostatin, we performed a series of tissue manipulations,
including removal of ectoderm, neural tube, notochord, and
floor plate, and we determined the influence of Sonic
hedgehog protein. Finally, we demonstrate that application
of Myostatin protein to developing limb muscle leads to the
down-regulation of Pax-3, Myf-5, and MyoD. The long-term
effect of Myostatin is a decrease in the amount of termi-
nally differentiated muscle.
MATERIALS AND METHODS
Preparation of Chick Embryos
Fertilised chicken eggs were incubated at 38°C, and the embryos
were staged according to Hamburger and Hamilton (1992). Experi-
ments were performed on embryos at stages 13–23, reincubated for
a total of 3 days, sacrificed, and processed for whole-mount in situ
hybridisation.
Myostatin and Sonic Hedgehog Bead Preparation
Recombinant Myostatin protein was purchased from R&D Sys-
tems. Sonic hedgehog (Shh) was a gift from Professor Andy McMa-
hon (Boston, MA). All proteins were applied to 80- to 120-m
Affigel beads (Sigma). The proteins were loaded onto beads as
described by Cohn et al. (1995). Myostatin was used at 0.3- to
1-mg/ml concentrations, and Shh was used at 8 mg/ml.
Bead Application and Microsurgical Procedures
For bead implantation, the dorsal ectoderm and mesenchyme of
the right wing or somites were punctured with an electrolytically
sharpened tungsten needle, and beads were inserted into the
punctured mesenchyme by using a blunt glass needle. Beads were
implanted at HH stages stated in the text.
For ectoderm removal, the ectoderm was stained with Nile Blue
in ovo using a blunt glass needle coated with 2.5% agar containing
2% Nile Blue. The ectoderm was peeled from the mesenchyme
immediately after staining. At thoracic level, ectoderm was re-
moved from stage 19–20 embryos extending from somites at
interlimb level and from the lateral side of the neural tube at a
dorsomedial limit down to the abdominal wall at a ventrolateral
limit. At limb level, ectoderm was removed from the dorsal and
ventral limb surface avoiding the limb margins, apical ectodermal
ridge, and the ectoderm overlying the zone of polarising activity of
HH stage 22–23 embryos.
Portions of unilateral halves of neural tube were removed at the
level of the segmental plate mesoderm as previously described
(Christ et al., 1992). Tissue extending over 8–12 prospective somite
length was removed.
Notochord and floor plate were removed at the level of the
segmental plate mesoderm by opening the neural tube along the
dorsal midline with a tungsten needle. Thereafter, a cut was made
on either side of the floor plate and the floor plate was removed
together with the attached notochord. The open neural tube was
closed by decreasing the surface tension, which was achieved by
removing 2 ml of albumin from the egg.
The intermediate third of the dermomyotome was removed over
the extent of four somites at HH stage 15–18 embryos. In a first
step, ectoderm was incised and lifted from the dermomyotome, and
in a second step, the intermediate dermomyotome was removed by
using a tungsten needle and a mouth-operated micropipette. After
tissue removal, the ectoderm was placed back in order to cover the
operation site. No enzymes were used in neural tube, notochord, or
dermomyotome removal.
For the generation of muscle-free limbs, somatic mesoderm of
the prospective wing area was isolated together with the overlying
ectoderm from quail embryos at HH stage 13–15. These wing
anlagen were grafted into the laterally opened coelomic cavity of
chick embryos at HH stages 15–17. After a reincubation period of
6–10 days, the host embryos were sacrificed, dissected, and pro-
cessed for in situ hybridisation.
Whole-Mount in Situ Hybridisation
All chick embryos were washed in PBS and then fixed overnight
in 4% paraformaldehyde at 4°C. Anti-sense RNA probes were
labelled with digoxigenin, and whole-mount in situ hybridisation
was performed as described by Nieto et al. (1996). The following
probes were used in this study: MyoD, clone CMD9 full 1.5-kb
length fragment (gift from Professor Bruce Patterson); Myf-5, a
clone kindly provided by Dr. Antony Graham. Pax-3, 645-bp
fragment corresponding to nucleotides 468-1113 (gift from Dr.
Martin Goulding); chick Myostatin, 1-kb fragment was a kind gift
from Professor Se Jin Lee; full-length cLmx-1 (3 kb) was size
reduced to 0.5-kb fragments by using alkaline hydrolysis as de-
scribed by Nieto et al. (1996); Lmx-1 was kindly provided by Dr, M.
Ensini; full-length cTbx-5 was kindly provided by Professor J. C.
Izpisua Belmonte. Whole-mount embryos were cryosectioned for
further histological examination.
Immunohistochemistry on Whole Mounts for the
Detection of Desmin
Embryos were fixed overnight in 4% paraformaldehyde (PFA),
dehydrated into 100% methanol, incubated for 1 h in 4:1 methanol/
H2O2 (6% final), washed in PBT (PBS containing 0.5% Triton).
Embryos were treated in Proteinase K (10 g/ml) and after a wash
in PBT, fixed in 4% PFA for 20 min. Following a brief wash in PBT,
embryos were incubated for 1 h in 10% horse serum (in PBT) and
then overnight with anti-Desmin monoclonal antibody (DAKO,
1:500, in horse serum/PBT). Embryos were extensively washed in
PBT and then incubated overnight in secondary antibody (alkaline
phosphatase-conjugated goat anti-mouse Ig antibody; Sigma, 1:500,
in horse serum/PBT). Subsequently, embryos were washed in PBT,
transferred in NTBT buffer (Nieto et al., 1996), incubated for 5–10
min in colour reagent (4.5 l NBT and 3.5 l BCIP in 1 ml
NTBT-buffer; Boehringer–Mannheim), washed in NTBT buffer,
cleared in dimethylformamide, and stored in 4% PFA.
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FIG. 4. Myostatin expression during head development. Red asterisk marks hypoglossal cord. (A) At HH stage 21, faint expression of
Myostatin is detectable in branchial arch 1 (arrowhead) and branchial arch 2 (arrow). (B) By HH stage 22, Myostatin expression in both
branchial arch 1 (arrowhead) and 2 (arrow) is evident at the proximal aspect. (C) By HH stage 23, the broad strong patch of expression in
branchial arch two (arrow) contrasts the faint bar of expression in branchial arch one (arrowhead). (D) Frontal section of HH stage 23 head
shows Myostatin expression in branchial arch 1 confined to the mesenchymal core (arrowhead) and contrasts the expression in branchial
arch 2, which extends up to the ectoderm (arrow).
FIG. 3. Tissue expression of Myostatin and muscle markers during wing bud development. All wing buds depicted following transverse
sectioning. (A) Myostatin expression in a dorsal (black arrow) and ventral mesenchymal position (white arrow) corresponding to MyoD
expression of dorsal (black arrow) and ventral premuscle masses (white arrow) in (B) of an HH stage 22 wing bud. Additional Myostatin
expression domain in the mesenchymal core (black arrowhead, in A). (C) Myostatin expression in the mesenchymal core of an HH stage
25 wing bud (arrowhead). Expression declines in the dorsal premuscle (arrow) and is down-regulated ventrally compared with the MyoD
expression of dorsal (black arrow) and ventral premuscle masses (white arrow) in (D). (E) Myostatin expression in a small dorsal muscle
domain (arrow) at HH stage 28 compared with Desmin expression, which marks ventral and dorsal muscle in (F). (G) Myostatin expression
in a small dorsal (black arrow) and ventral muscle domain (white arrow) at HH stage 30. (H) At HH stage 29, zeugopod muscle splitting is
well in progress as shown by MyoD expression. (I–K) Different levels of Myostatin expression in different zeugopod muscles of an HH stage
31 wing (I) and HH stage 32 wing (K) compared with the muscle pattern after Desmin staining (J). Note heterogeneous Myostatin expression
within single muscles. (L) Diagrammatic representation of (K) shows muscles with high Myostatin expression in dark blue, low expression
in medium blue, and no expression in light blue. Radius (R) and ulna (U). (1) Anconeus, (2) extensor digitorum communis, (3 and 4)
entepicondyloulnaris, extensor medius longus, extensor indicis longus, (5) extensor metacarpi ulnaris, (6) extensor metacarpi radialis, (7)
pronator superficialis, (8) pronator profundus, (9 and 10) flexor digitorum profundus, and (11 and 12) flexor carpi ulnaris muscles.
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RESULTS
Expression of Myostatin during Chick Somite
Development
Expression of Myostatin was first detected by whole-
mount in situ hybridisation in HH stage 15 chick embryos
with transcripts localised in the ventrolateral portion of the
four to five most rostrally situated somites (Fig. 1A). Addi-
tionally, faint expression was found throughout somites I-II
and in the tail bud. By HH stage 17, Myostatin transcripts
were no longer detectable in the caudal region of the
embryo (Fig. 1B). Rostrally, the expression was found in the
ventrolateral portion of all occipital and cervical somites.
Myostatin expression was also detected in the prospective
tongue muscle-forming region from HH stage 17 onwards
(Figs. 1B–1E). At HH stage 19, faint expression was addi-
tionally detected in somites at interlimb level (Fig. 1C). At
stage 20, all but the most caudal somites expressed Myo-
statin, which nevertheless eventually up-regulated the gene
at later stages (Figs. 1D–1H). In addition to the expression in
the centre of the dermomyotome, a line of expression was
present at the ventral side of somites, which corresponded
to cells situated next to the hypaxial bud of the dermomyo-
tome, intermediate mesoderm, and at the endodermal pli-
cae of the coelomic cavity (Figs. 1D, 2A, and 2B). Transverse
sections at the thorax level of HH stage 20 embryos re-
vealed strong Myostatin expression in the centre of the
dermomyotome, which extended dorsomedially and ven-
trolaterally during later stages (Figs. 2A and 2C). Expression
was never detected in the dorsomedial or ventrolateral
dermomyotomal lips. In somites at thorax level of HH stage
22 embryos, Myostatin expression in the dermomyotome
extended to the ectoderm, thus, into a region which forms
the dermis of the back later in development (Fig. 2C).
Additionally, transverse sections of somites at thorax level
of HH stage 22 embryos revealed a differential expression of
Myostatin in the myotome along its craniocaudal axis. The
centre of the myotome did not express Myostatin (Fig. 2C),
whereas expression was found in the rostral and caudal part
of the myotome (Figs. 2D and 2F). At stage 25, Myostatin
expression was found in the dermomyotome and in the
hypaxial part of the myotome, and additionally in the
dorsomedial tip of the myotome (Fig. 2E). At later stages,
dermomyotomal expression was down-regulated, and at
HH stage 30, Myostatin expression was found only in
hypaxial muscle (Figs. 1I and 1J).
Therefore, Myostatin expression was detected relatively
late during somite development, well after compartmental-
isation of the somite in its derivatives, dermomyotome,
myotome, and sclerotome. Strong expression was detected
in the intermediate portion of the dermomytome and myo-
tome as well as in prospective subectodermally located
dermal cells.
Myostatin Expression during Limb Development
In the limbs, Myostatin expression was first detected in a
small proximomedial domain in both wing and leg buds at
HH stage 21, which extended distally during development
(Figs. 1E–1H). Transverse sections of wing buds at HH stage
22 revealed that the expression was composed of three
mesenchymal domains (Fig. 3A). One was dorsally situated
and corresponded approximately to the MyoD expression
domain of the dorsal premuscle mass (Figs. 3A and 3B). The
second was ventrally situated and corresponded approxi-
mately to the MyoD expression domain of the ventral
premuscle mass (Figs. 3A and 3B). These muscle related
expression domains were down-regulated during the follow-
ing stages compared with the MyoD expression of pre-
muscle masses at HH stage 25 (Figs. 3C and 3D). The third
more centrally located expression domain corresponded
approximately to the mesenchymal core of the limb bud
and was present up to HH stage 28 (Figs. 3A and 3C).
Myostatin was reexpressed in limb muscle from HH stage
28 onwards and was first detected at low levels of tran-
scripts in proximal limb muscle (data not shown). Addition-
ally, we detected a small expression domain dorsal to the
radius that represented a part of the zeugopod muscle when
compared with Desmin expression at this stage (Figs. 3E
and 3F). At HH stage 29, zeugopod muscle started to split
into individual muscles as shown by the expression of
MyoD (Fig. 3H). At HH stage 30, a small Myostatin expres-
sion domain was detected in the ventral limb muscle in
addition to the small dorsal expression domain (Fig. 3G).
However, these expression domains could not be correlated
to specific muscles. From HH stage 31 onwards, expression
became confined to individual muscles (Fig. 3I). Remark-
ably, only some muscles expressed Myostatin, and the level
of expression differed between individual muscles com-
pared with the Desmin expression, which marks all muscle
at HH stage 32 (Figs. 1K and 1L, and 3J–3L). Only pronator
superficialis and extensor metacarpi ulnaris muscles ex-
pressed Myostatin at high levels. Extensor metacarpi radia-
lis, pronator profundus, flexor digitorum profundus, flexor
digitorum superficialis, and flexor carpi ulnaris muscles
expressed Myostatin at low level and remaining muscles
showed almost no expression. Moreover, even within single
muscles there was heterogeneity in expression (Figs. 3K and
3L). In summary, Myostatin was initially expressed in limb
mesenchyme in both myogenic and nonmyogenic regions.
During late limb bud stages, Myostatin expression was
found within specific muscles.
Expression of Myostatin during Head Development
Development of the head muscle differs from that of the
body in terms of its origin and the molecular pathways for
its differentiation (Mootoosamy and Dietrich, 2002). Head
muscle does not develop from somites but originates pri-
marily from head mesoderm (Wachtler and Jacob, 1986).
Additionally, head muscle does not express Pax-3 (Franz et
al., 1993; Tajbakhsh et al., 1997).
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Expression of Myostatin in the head became detectable at
HH stage 20 and was clearly evident at HH stage 21 with
two zones of expression: a bar of transcripts in the branchial
arch one and a patch of expression in brachial arch two (Fig.
4A). One stage later and following further outgrowth of the
branchial arches, it became evident that the expression of
Myostatin was more pronounced at the proximal aspect and
did not extend to the distal margins (Fig. 4B). By HH stage
23, the broad strong patch of expression in branchial arch
two contrasted the faint bar of expression in branchial arch
one (Fig. 4C). Frontal sections revealed that the expression
in branchial arch one was confined to a central portion of
the mesenchyme, whereas in branchial arch two, mesen-
chymal expression extended to the ectoderm (Fig. 4D).
Myostatin expression was not detected in any other
branchial arch. Therefore, the Myostatin expression pattern
in the head was related to the identity of the branchial arch.
In addition, expression of the gene was found in both the
central and subectodermal mesenchyme.
Regulation of Myostatin Expression in the Somites
Somite development, and in particular determination and
differentiation of somite-derived cell lineages, depends on
signals which emanate from neighbouring tissues. In this
section, we examined whether Myostatin expression in
somites relies on extrinsic signalling and whether
Myostatin-expressing cells belong to specific somite-
derived cell lineages. In the first set of experiments, we
determined the influence of the ectoderm as we have
previously shown that this tissue maintains Pax-3 expres-
sion in the dermomytome (Amthor et al., 1999). We re-
moved trunk ectoderm only on the right side of HH stage
19–20 embryos and found a down-regulation of Myostatin
expression on the operated side 26 h after operation (n  6,
Fig. 5A). The dorsomedial–ventrolateral extension of the
dermomyotome was shortened on the operated side com-
pared with contralateral (Fig. 5B). At the unoperated side,
Myostatin expression was found predominantly in the
dermomyotome, subectodermal mesenchyme, and myo-
tome. After ectoderm removal, however, Myostatin expres-
sion was lost in all locations except a central domain that
corresponded to the central part of the myotome (Fig. 5B).
Therefore, ectodermal signalling sustains dermomyotomal
expression of Myostatin, but expression in the myotome
does not rely on this tissue.
Application of Shh to the mature somites has been shown
to transiently induce muscle differentiation at the expense
of the proliferating Pax-3-expressing myogenic precursors
(Amthor et al., 1999). We implanted Shh beads to the right
side of the trunk at HH stages 18–19 embryos prior to the
onset of Myostatin expression in somites (n  9). Following
a reincubation of 12 h, embryos developed to HH stage 21
and expressed Myostatin in the central part of the dermo-
myotome and subectodermal mesenchyme on the unoper-
ated left side (Figs. 5C and 5D). Exposure to Shh on the right
side of the trunk resulted in complete lack of Myostatin
expression on the operated side (Figs. 5C and 5D). Subse-
quently, we implanted Shh beads in the trunk of embryos at
HH stage 20 (n  4) for a period of 31 h (embryos developed
to HH stage 26). On the unoperated left side, Myostatin
expression resided in the ventral part of the myotome (Figs.
5E and 5F). Interestingly, on the operated side, Myostatin
expression was now up-regulated. The expression domain
was enlarged and corresponded to an enlarged ventral part
of the myotome (Figs. 5E and 5G).
We performed ablation experiments that complimented
the application of Shh. We tested whether Myostatin ex-
pression in somites depends on Shh signalling and removed
notochord and floor plate (which both express Shh) prior to
somite formation at prospective thorax level of HH stage
11–13 embryos (n  9). Forty-eight hours after operation,
embryos developed to HH stages 21–23. We found that
without a floor plate and notochord, somites at the site of
operation appeared considerably smaller than in unoperated
embryos (Fig. 5H). Furthermore, somite-derived structures
(dermomyotome, myotome, and sclerotome) could not be
morphologically identified (Fig. 5I). Despite this, we found
strong Myostatin expression at the site of operation that
extended ventrally to a position where the sclerotome
would normally develop (Fig. 5I). Furthermore, expression
was considerably up-regulated in somites at the site of
operation compared with adjacent unoperated regions.
Therefore, notochord and floor plate, which both are tissues
that express Shh, inhibit Myostatin expression.
The dorsomedial part of the dermomyotome gives rise to
epaxial muscle and its development depends on neural tube
signalling (Bober et al., 1994; Rong et al., 1992). In the next
experiment, we determined whether the expression of Myo-
statin in the dermomyotome depends on neural tube sig-
nals by ablating the right half of the neural tube prior to
somite formation at prospective thorax level of HH stage
13–14 chick embryos (n  4). Two days after unilateral
neural tube ablation, somite tissue was much smaller on
the operated side compared with the unoperated left side
(Fig. 5J). The somite tissue was morphologically well differ-
entiated into dermomyotome, myotome, and sclerotome.
However, even though the dermomyotome and the myo-
tome were shortened in their dorsomedial-to-ventrolateral
extension, we found strong Myostatin expression in the
remaining dermomyotome, and the size of the expression
domain was only slightly smaller than on the unoperated
left side. This experiment suggests that only a minority of
Myostatin-expressing cells depends on neural tube signal-
ling and that the majority of Myostatin-expressing cells are
confined to the hypaxial and not to the epaxial somite
domain.
Regulation of Myostatin Expression in the Limb
Limb ectoderm sustains proliferation in subectodermal
mesenchyme and inhibits muscle differentiation and chon-
drogenesis (Amthor et al., 1998; Solursh and Reiter, 1988).
We determined the influence of the ectoderm on Myostatin
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FIG. 5. Regulation of Myostatin expression during somite development. (A) One day after removal of trunk ectoderm, Myostatin
expression in somites is shortened in the mediolateral extension (arrows) compared with the unoperated left side (arrowheads). (B)
Transverse section of whole mount shown in (A). On the unoperated left side, expression is found in the dermomyotome and myotome
(arrowhead), whereas on the operated side, only the central part of the myotome expresses Myostatin (arrow). Bracket marks extension of
ectoderm removal. (C, D) Twelve hours after exposure to Shh, Myostatin expression is completely down-regulated in the dermomyotome
near the implanted bead (green arrowhead) compared with the unoperated left side. (E) Thirty-one hours after exposure to Shh, Myostatin
is reexpressed, and somites appear enlarged (arrows). Bead (green arrowhead). (F, G) Transverse section of (E) reveals that the ventral part
of the myotome, which expresses Myostatin, is enlarged (G, arrow) compared with the unoperated left side (F, arrowhead). Bead (green
arrowhead). (H) Two days after removal of floor plate and notochord, the embryo developed a significant scoliosis at the operation site, but
Myostatin is still strongly expressed in the somites (arrows). (I) Transverse section at the operation site of the whole mount shown in (H)
reveals ventral extension of the Myostatin expression domain in lack of floor plate and notochord signalling compared with Fig. 2A. The
somite tissue is smaller, and a dermomyotome, myotome, and sclerotome cannot be morphologically identified (arrows). (J) After removal
of the right half of the neural tube, the ipsilateral somite tissue is smaller but well differentiated in dermomyotome, myotome, and
sclerotome. The dermomyotome highly expresses Myostatin (arrow). The expression domain is only slightly smaller compared with the
unoperated left side (arrowhead). Remaining half of neural tube (green arrowhead).
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expression and ablated the right wing ectoderm from both
the dorsal and ventral surfaces at HH stage 22–23 (n  7).
Care was taken not to damage the distal ectoderm, thereby
maintaining apical ectodermal ridge and progress zone
integrity. Following a reincubation period of 13 h, we
observed a dramatic increase in Myostatin expression, al-
though operated wings appeared smaller than unoperated
left wings (Fig. 6A). Transverse sections revealed that not
only was the Myostatin expression more intense than
normal, but that the domain of expression had expanded in
both the dorsoventral and anteroposterior axes (Figs. 6B and
6C). Myostatin expression extended to the operated surface
following ectoderm removal compared with the normal
expression at this stage in the unoperated left wing, which
is only confined to the mesenchymal core. Therefore,
during early limb bud development, expression of Myosta-
tin in subectodermal regions is inhibited by limb ectoderm.
Sonic hedgehog (Shh) has been previously shown to act
synergistically with limb ectoderm to maintain Pax-3-
linked proliferation of limb muscle precursors and to pre-
vent precocious muscle differentiation (Amthor et al., 1998;
Duprez et al., 1998). Implantation of beads soaked in Shh in
wing bud mesenchyme at HH stage 20 resulted in a com-
plete down-regulation of Myostatin expression 20 h after
operation compared with the unoperated left wing (n  11,
Fig. 6D). Operated wings were enlarged compared with the
unoperated wings. However, longer reincubation (31 h, n 
4) resulted not only in the reappearance of Myostatin
expression in the operated wings, but the expression do-
main was enlarged (Figs. 6G and 6H). Transverse sections
FIG. 6. Regulation of Myostatin expression during limb muscle development. (A) Up-regulation of Myostatin expression (arrow) after
removal of dorsal and ventral wing ectoderm, although the size of the wing appears smaller compared to the unoperated left wing. (B, C)
Transverse sections of wing buds shown in (A). Extension of the Myostatin expression domain to the dorsal (arrow) and ventral
subectodermal mesenchyme (arrowhead) after ectoderm removal (C) compared with the expression in the mesenchymal core of the
unoperated left wing (B). (D) Complete down-regulation of Myostatin 22 h after Shh bead implantation (arrow) compared with the
unoperated left wing. Bead (green arrowhead). (E) Wing bud, which failed to be populated with muscle after heterotopic development, still
expresses Myostatin in a central domain (arrow). (F) Transverse section of the whole mount shown in (E) reveals a faint Myostatin
expression in the mesenchymal core (arrow). (G, H) Thirty-one hours after Shh bead implantation, the Myostatin expression domain (arrow)
and the whole wing bud enlarged (H) compared with the unoperated left side (G). (I, J) Transverse sections of wings shown in (G) and (H)
reveals that the Myostatin expression domain in the mesenchymal core enlarged (arrow), but there is no ectopic expression (J) compared
with the unoperated left wing (I). Bead (green arrowhead).
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revealed that the enlarged Myostatin expression domain
still resided in the mesenchymal centre of the enlarged
operated wing compared with the unoperated wing (Figs. 6I
and 6J).
We were intrigued by the expression of Myostatin in the
central region of the limb bud that is not populated by
myogenic cells. We grafted the prospective wing-forming
region into the coelomic cavity before myogenic cells
migrated into wing bud mesenchyme. Such operation re-
sults in the development of muscle free wings (Christ et al.,
1977). Wing buds were grown until they reached a stage
equivalent to HH stage 25. We show that heterotopically
developed wings expressed Myostatin in the normal central
domain, but the intensity of expression was much weaker
than in normal wings (Figs. 6E and 6F; compare with the
unoperated left wing in Figs. 6A and 6B).
Effect of Myostatin Protein on Limb Muscle
Development
We explored the function of Myostatin during muscle
development and implanted beads soaked in Myostatin into
the dorsal subectodermal mesenchyme of right wings of HH
stage 21–22 embryos and analysed the expression of the
myogenic marker genes Pax-3, Myf-5, MyoD, and Desmin
at various intervals thereafter. Beads were implanted in the
centre of the dorsal premuscle mass at HH stage 21, when
Pax-3, Myf-5, and MyoD expression has already been estab-
lished (Amthor et al., 1998; Delfini et al., 2000). Implanta-
tion of beads soaked in 1 mg/ml Myostatin resulted in a
down-regulation of the expression of Pax-3, Myf-5, and
MyoD within 6 h following operations compared with the
unoperated left wings (Pax-3, n  4; Myf-5, n  5; MyoD,
n 6; Figs. 7A, 7C, and 7E). Down-regulation of these genes
occurred predominantly in the dorsal premuscle masses,
especially in the proximity of the beads and to a consider-
ably lower extent (if at all) in the ventral premuscle masses.
The presence of Myostatin beads did not completely stop
further development of premuscle masses as the expression
domains of Pax-3, Myf-5, and MyoD enlarged following 24 h
after operation compared with 6 h after operation. Signifi-
cantly, however, the total size of the expression domains
were smaller compared with the unoperated left wings (n 
7 for Pax-3; n  3 for Myf-5; n  12 for MyoD; Figs. 7B, 7D,
and 7F). Furthermore, at the site of the implanted beads,
there was a lack of Pax-3, Myf-5, and MyoD expression.
Finally, we tested whether the effect of Myostatin decreas-
ing the transcription of Pax-3, Myf-5, and MyoD impairs
muscle growth. We implanted beads soaked in 1 mg/ml
Myostatin at HH stage 21 and analysed the expression
pattern of Desmin 72 h after operation (n  5). After this
interval, beads were approximately located at the elbow
joint. In most cases, the stylo- and zeugopodium appeared
shortened. We found a considerable lack of desmin expres-
sion of dorsal stylopod, zeugopod, and autopod muscle in all
cases examined. Even in cases in which overall limb out-
growth appeared normal, dorsal zeugopod and autopod
muscles were almost completely abolished (Fig. 7G). Inter-
estingly, as for Pax-3, Myf-5, and MyoD expression, ventral
muscle did not seem to be affected when Myostatin beads
were implanted on the dorsal side of the developing wing.
Since Myostatin beads were implanted at HH stage 21 wing
buds, thus, approximately 24 h before the onset of Desmin
expression (HH stage 25 during normal development), it
seems likely that Myostatin effects Desmin expression
indirectly and via the down-regulation of Pax-3, Myf-5, and
MyoD expression rather than having a direct effect.
We next analysed whether Myostatin acts concentration-
dependent on myogenic cells and applied beads soaked in
0.33 mg/ml Myostatin to wing buds similar to above
experiments. Exposure to low Myostatin concentration still
resulted in a down-regulation of Pax-3 and MyoD expres-
sion 1 day after bead implantation (Pax-3, n 5; MyoD, n
5; data not shown). However, the effect was less obvious
and the range of down-regulation shorter compared with
the effect of high concentrated Myostatin. Thus, Myostatin
acts concentration-dependent on myogenic cells.
We analysed whether the effect of Myostatin on myo-
genic cells is specific and tested the expression of Tbx-5 and
Lmx-1, markers for wing mesenchyme and dorsal limb
mesenchyme, respectively (n  4 for Tbx-5, n  3 for
Lmx-1). Twenty-four hours after Myostatin bead implanta-
tion into the right wings, there was no difference in the
expression of either gene compared with the unoperated left
wings (data not shown). Thus, the effect of Myostatin on
Pax-3, Myf-5, and MyoD expression seems to be specific and
not caused by unspecific cell toxicity. Implantation of beads
soaked in PBS only, into right wing buds of HH stage 21
embryos, did not change the expression of Pax-3, MyoD,
and Desmin compared with unoperated left wings, nor did
control beads change the ultrastructure of the mesenchyme
(Amthor et al., 1998, 2002).
In summary, Myostatin decreases expression of Pax-3 and
Myf-5, genes which are associated with the proliferation of
myogenic cells (Amthor et al., 1998; Delfini et al., 2000).
Furthermore, Myostatin also decreases expression of MyoD,
which is associated with the onset of muscle differentia-
tion. Such negative effect on the gene expression of key
myogenic determinants eventually results in a deficit of
terminally differentiated muscle.
DISCUSSION
Myostatin is a diffusible growth factor, which functions
to limit the size of the musculature during growth of the
organism (Lee and McPherron, 1999). In absence of Myosta-
tin, the organism develops hypertrophy and hyperplasia of
skeletal muscle (McPherron et al., 1997; McPherron and
Lee, 1997). The intriguing property of Myostatin to restrict
muscle size without influencing positioning and patterning
of muscle led us to determine the exact pattern and regu-
lation of Myostatin expression and the effect of Myostatin
protein during embryonic development.
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Myostatin and Myotome Development
Axial muscle development begins with the involution of
differentiating muscle cells of the dermomyotome, which
forms the segmentally organised muscle anlagen of the
trunk, called the myotomes. Although myotomal cells are
recruited from all edges of the dermomyotome, it is thought
that the dorsomedial and ventrolateral edges (synonyme
lips) exert highest growth activity for myotome formation
(Cinnamon et al., 1999; Denetclaw et al., 1997, 2001;
Denetclaw and Ordahl, 2000; Ordahl et al., 2001; Kahane et
al., 2001). This is reflected by a strong expression of Pax-3
and a high rate of proliferation at these sites (Amthor et al.,
1999). We show that expression of Myostatin begins after
somites are differentiated in dermomyotome, myotome,
and sclerotome—not before HH stage 19 at the thoracic
level. Myostatin is initially strongly expressed in the der-
momyotome but excluded from the dorsomedial and ven-
trolateral dermomyotomal lips. Thus, Myostatin is not
expressed at stages and sites that would interfere with the
qualitative development of the myotome. The expression of
Myostatin in the centre of the dermomyotome suggests
that it reduces participation of expressing cells in myotome
formation and therefore prevents hyperplasia. However, it
is not that cells of the intermediate third of the dermomyo-
tome cannot participate in muscle development. Huang and
Christ (2000) followed the fate of intermediate dermomyo-
tomal cells and found that they contribute to the hypaxial
myotome. Therefore, cells, which express Myostatin, are
biased towards the hypaxial lineage. This conclusion is
reinforced by data from the somite manipulation experi-
ments: lack of neural tube signalling results in epaxial
muscle failing to form (Bober et al., 1994; Christ et al.,
1992; Rong et al., 1992). We show that, after neural tube
removal, the size of the Myostatin expression domain is
only slightly reduced. Thus, the majority of Myostatin-
expressing cells are confined to the hypaxial somite do-
main. This becomes evident at later stages at which Myo-
statin expression is found in hypaxial but not in epaxial
muscle of the trunk.
We previously have shown that trunk ectoderm main-
tains proliferation of dermomyotomal cells (Amthor et al.,
1998). Here, we show that dermomyotomal but not myo-
tomal Myostatin expression depends on ectoderm signal-
ling. Thus, it appears that Myostatin-expressing cells of
the dermomyotome are linked to proliferation, whereas
Myostatin-expressing cells of the myotome are postmi-
totic. We also have previously shown that treatment of
mature somites with Shh results in a transition of
dermomyotomal-located Pax-3-expressing cells into preco-
cious MyoD expression, which expands the myotome. The
switch from losing dermomyotomal identity to expressing
myotomal marker occurs within 12 h after Shh treatment
(Amthor et al., 1998). These results are compatible with the
finding of our present study because dermomyotomal-
expressed Myostatin is lost within the same time period (12
h) after Shh treatment. Interestingly, although Shh treat-
ment results in a loss of dermomyotomal Myostatin expres-
sion, there was no immediate up-regulation of Myostatin in
the myotome in contrast to the precocious up-regulation of
MyoD after the same procedure. However, Myostatin ex-
pression was up-regulated after an extended period follow-
ing Shh exposure and marked the expanded myotome.
Notochord and floorplate express Shh (Marti et al., 1995).
After removal of both structures, dermomyotomal markers
expand ventrally because ventrally located somite cells are
not induced to form sclerotome-derived structures (Amthor
et al., 1996; Christ et al., 2000). We show that, after
notochord and floorplate removal, Myostatin expression
extends ventrally, which indicates that Myostatin expres-
sion marks cells of dorsal somite identity. Thus, during
somite development, Myostatin is expressed in defined
somite compartments, but the timing of Myostatin expres-
sion in these compartments was not experimentally al-
tered.
We observed that the expression of Myostatin in the
dermomyotome extends to the ectoderm. Thus, Myostatin
is expressed in cells, which will form part of the dermis of
the back. This is interesting as only a few genes, e.g.,
Dermo-1 and Frizzled-1, have been found to be expressed in
early stages of dermis development (Li et al., 1995; Schmidt
et al., 2000). The subectodermal expression of Myostatin at
this site could simply be “passive,” i.e., a vestige of the
expression found in the precursor cell type, which is derived
from the dermomyotome. A more interesting hypothesis
would be the active involvement of Myostatin in dermis
formation. Myostatin, which we have shown to prevent
muscle differentiation, could permit cells to adopt a dermis
fate. In fact, in Myf-5/ mice, cells, which normally would
differentiate in muscle, are specified to form dermis or
cartilage (Tajbakhsh et al., 1996). Although dermis defects
were not reported in Myostatin/ mouse (McPherron et al.,
1997), dermis can originate from multiple sources (Christ
and Ordahl, 1995; Le Lievre and Le Douarin, 1975; Olivera-
Martinez et al., 2000). Future work will investigate this
hypothesis of dermis development.
Myostatin and Limb Muscle Development
Myostatin expression was detected in both myogenic and
nonmyogenic regions during limb outgrowth. Myostatin
expression resides at positions where MyoD-expressing
cells of dorsal and ventral premuscle masses are localised
and at a position where chondrogenic cells are found
(Amthor et al., 1998; Mallein-Gerin et al., 1988). However,
expression in myogenic regions is down-regulated at ap-
proximately HH stage 23 and only reappears at HH stage 28.
At this stage, splitting of proximal muscle is well under-
way. Thus, it appears that Myostatin expression is not
related to muscle patterning and that the onset of expres-
sion follows the splitting of muscle and not vice versa.
Removal of limb ectoderm results in a dramatic decrease
in mitotic levels in the subectodermal mesenchyme
(Amthor et al., 1998). However, following an identical
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procedure, Myostatin expression is extended to the exposed
surface. Thus, during limb development, Myostatin expres-
sion is found in nonproliferating mesenchymal cells. We
previously have shown that the lack of proliferation signals
emanated by the ectoderm results in muscle precursors to
prematurely differentiate. However, sustained muscle de-
velopment is inhibited, and we have proposed that this is
due to the lack of precursors (which all precociously differ-
entiated), which would be required for long-term growth
(Amthor et al., 1998). Sonic hedgehog, similar to the action
of ectoderm, initially inhibits MyoD expression and tran-
siently prevents muscle differentiation in the limb. Shh,
probably via BMPs, induces the expression of Pax-3 at the
expense of MyoD. After a prolonged period of Pax-3-
associated proliferation, more cells differentiate and muscle
enlarges (Amthor et al., 1998; Duprez et al., 1998). Interest-
ingly, Shh stimulates not only muscle growth, but enlarges
the entire limb. Similarly, in this study, we show that
FIG. 7. Effect of ectopic myostatin on limb muscle development. Beads soaked in Myostatin (1 mg/ml) were implanted into the wing bud
at stages 21–22. (A) Down-regulation of Pax-3 expression (arrow) 6 h after Myostatin bead implantation in the right wing compared with
the unoperated left wing. Bead (green arrowhead). (B) Twenty-four hours after Myostatin bead implantation, Pax-3 expression is still
down-regulated in the operated right wing compared with the unoperated left wing. Bead (green arrowhead). (C) Down-regulation of Myf-5
expression (arrow) 6 h after Myostatin bead implantation in the right wing compared with the unoperated left wing. Beads (green
arrowhead). (D) Twenty-four hours after Myostatin bead implantation, Myf-5 expression is still down-regulated in the operated right wing
compared with the unoperated left wing. Beads (green arrowhead). (E) Complete loss of MyoD expression (arrow) 6 h after Myostatin bead
implantation in the right wing compared with the unoperated left wing. Bead (green arrowhead). (F) Twenty-four hours after Myostatin bead
implantation, MyoD expression is still down-regulated in the operated right wing compared with the unoperated left wing. Bead (green
arrowhead). (G) Exposure to Myostatin beads results in a lack of muscle especially in the zeugopod and autopod (arrows) in the operated
right wing 72 h after operation compared with the unoperated left wing as revealed by Desmin expression. Beads (green arrowheads).
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Myostatin expression is transiently down-regulated after
exposure to Shh, but the Myostatin expression domain in
the mesenchymal core eventually enlarges. This shows that
signals such as ectoderm and Shh, which stimulate growth
of limb tissues, inhibit expression of Myostatin.
We have shown that limb buds devoid of muscle still
express Myostatin, albeit to a lesser extent than normal,
which shows that nonmyogenic cells can express Myosta-
tin. Centrally located mesenchymal cells normally develop
into long bone rudiments (Mallein-Gerin et al., 1988).
However, Myostatin is unlikely to influence cartilage de-
velopment as the femur in Myostatin/ is relatively nor-
mal (Hamrick et al., 2000). We suggest that, rather than
acting on cartilage tissue, the centrally situated Myostatin
expression acts to limit muscle growth of nearby premuscle
masses. Thus, Myostatin acts in a similar fashion to Nog-
gin, which is also expressed in the mesenchymal core of
early limb buds and has been shown to inhibit muscle
growth (Amthor et al., 1998, 2002).
Remarkably, at late embryonic stages, Myostatin is up-
regulated in a subset of limb bud muscles, and even within
single muscles, Myostatin expression is not homogeneous.
This expression pattern implies that Myostatin regulates
differential growth of muscles. So far, it has not been
reported whether size proportion between muscles is con-
served in lack of Myostatin. Therefore, we currently can
only speculate why the muscle size needs to be restricted
during development. We suggest that, for optimal perfor-
mance and reproductive fitness during normal life and
under selective pressure, it is necessary to prevent overpro-
duction of muscle while retaining the possibility to create
more muscle in order to adapt to changing conditions.
These changes could be simply brought about by modulat-
ing the expression of a single factor, such as Myostatin. It
would be interesting to determine the survival fitness
credentials under natural selection pressure in animals
lacking Myostatin.
Application of Myostatin protein to developing limb buds
results in a down-regulation of Pax-3 and Myf-5 expression,
both genes which are associated with proliferation of myo-
genic precursors (Amthor et al., 1998, Delfini et al., 2000).
Myostatin was also able to completely abolish the expres-
sion of MyoD, an early marker of muscle differentiation.
Such inhibition of proliferation and differentiation of myo-
genic cells eventually results in a considerably decreased
muscle mass production. Previous experiments suggested
that limb muscle precursors either proliferate, differentiate,
or are forced into apoptosis upon action of a wide range of
growth factors, including Follistatin, Noggin, Shh, BMP-2,
-4, and -7, and Delta (Delfini et al., 2000; Amthor et al.,
1998, 2002; Hirsinger et al., 1997; Pourquie et al., 1996).
Remarkably, myogenic cells, when exposed to Myostatin,
loose gene expression of key transcription factors, which
mark early muscle development. A possible explanation
would be that myogenic cells are forced into programmed
cell death; however, preliminary experiments fail to show
this (data not published). Intriguingly, the effect of Myosta-
tin appears to be stronger 6 h after treatment compared with
24 h after treatment. One possible explanation for these
observations is that the effect of Myostatin to down-
regulate Pax-3, MyoD, and Myf5 is reversible. In this
scenario, Myostatin would transiently delay muscle devel-
opment, but once its potency had diminished, cells would
be able to reenter the myogenic programme. Therefore,
while the cells are not expressing Pax-3, the proliferating
muscle precursor pool is not being expanded at its usual
rate. Once the effect of ectopic Myostatin has worn off, the
number of precursor cells that are able to rejoin the myo-
genic programme is considerably lower than that which
would have normally developed. This suggestion implies
that myogenic cells in the presence of Myostatin retain
myogenic identity, albeit deprived of Pax-3, Myf-5, and
MyoD expression. Another explanation for the loss of
muscle is that myogenic cells loose their commitment
towards the muscle lineage when exposed to Myostatin and
adopt a differing fate. There is experimental precedent for
this hypothesis from the elegant experiments of Tajbakhsh
et al. (1996). They have demonstrated that, in lack of Myf-5
(a gene that we have shown to be down-regulated by
Myostatin), cells that would normally become muscle,
develop into cartilage, bone, or dermal tissues. We currently
investigate the fate of cells which have lost expression of
myogenic marker genes after being exposed to Myostatin.
Myostatin and Head Development
In the head, expression of Myostatin only encompassed a
small proportion of cells that develop into muscle. Expres-
sion of Myostatin appeared much later than expression of
Myf-5 and MyoD (Hacker and Guthrie, 1998). Furthermore,
whereas Myf-5 is expressed in branchial arches 1–3, expres-
sion of Myostatin was confined to branchial arches 1 and 2.
However, even within these regions, its expression did not
extend to the same proximal–distal extent as Myf-5 expres-
sion, and, furthermore, expression was not confined to the
core. The later observation is particularly interesting as it
suggests that Myostatin expression may not be restricted to
cells which originates from head mesenchyme, but that
neural crest cells surrounding the core can also express the
gene. This observation highlights the fact that, in myogenic
regions, Myostatin can be expressed by both muscle and
nonmuscle cells.
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